Clinical features associated with improvement of fatty liver disease

被引:7
作者
Park, SH
Kim, BI
Kim, HJ
Kim, H
Kim, SH
Park, DI
Cho, YK
Sung, IK
Sohn, CI
Jeon, WK
Keum, DK
机构
[1] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Div Gastroenterol,Dept Internal Med, Seoul 110746, South Korea
[2] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Lab Med, Seoul, South Korea
关键词
fatty liver disease; bodyweight; low-density lipoprotein cholesterol;
D O I
10.1111/j.1445-5994.2005.00887.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We presumed that identification of the factors associated with improvement of fatty livers disease (FLD) would support the therapeutic options for FLD. The goal of this study was to clarify what clinical characteristics are associated with biochemical and sonographic improvements in the non-alcoholic population with fatty livers. Methods: A total of 615 non-alcoholic men had elevated alanine aminotransferase (ALT) (>= 40 IU/L) levels and sonographic evidence of a fatty liver, and their clinical characteristics were assessed at the beginning of the study and after 1 year of follow up. The improvement was defined as combination of normal ALT level and negative sonography for hepatic fat after 1 year. Programmed intervention or medications were not applied in this study population. Results: The overall rate of improvement of FLD after a 1-year follow up was 37/615 (6.0%). The improvement was strongly associated with decrement of changes in bodyweight, body mass index, waist circumference, gamma-glutamyltransferase, fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein cholesterol, total cholesterol/high-density lipoprotein cholesterol ratio and homeostasis model assessment. Multivariate analysis showed that decrement of changes in bodyweight (odds ratio (OR) = 1.56; 95% confidence interval (95% CI): 1.27-1.92) per 1 kg, body mass index (OR = 2.42; 95%CI: 1.58-3.71) per 1 SD (0.8 kg/m(2)), waist circumference (OR = 2.13; 95% CI: 1.02-4.54) per 1 cm, and low-density lipoprotein cholesterol (OR= 1.64; 95% CI: 1.05-2.56) per 1 SD (22 mg/dL) were all independent predictors for improvement of FLD. Conclusions: These results suggest that the reduction of bodyweight is a major key point for the improvement of FLD.
引用
收藏
页码:473 / 477
页数:5
相关论文
共 21 条
[1]   Non-alcoholic fatty liver syndrome: A hepatic consequence of common metabolic diseases [J].
Angelico, F ;
Del Ben, M ;
Conti, R ;
Francioso, S ;
Feole, K ;
Maccioni, D ;
Antonini, TM ;
Alessandri, C .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2003, 18 (05) :588-594
[2]   Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis [J].
Angulo, P ;
Keach, JC ;
Batts, KP ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1356-1362
[3]   A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [J].
Basaranoglu, M ;
Acbay, O ;
Sonsuz, A .
JOURNAL OF HEPATOLOGY, 1999, 31 (02) :384-384
[4]  
Chen QK, 2004, WORLD J GASTROENTERO, V10, P899
[5]   Nonalcoholic fatty liver disease [J].
Clark, JM ;
Brancati, FL ;
Diehl, AM .
GASTROENTEROLOGY, 2002, 122 (06) :1649-1657
[6]   Nonalcoholic fatty liver disease: is all the fat bad? [J].
Clouston, AD ;
Powell, EE .
INTERNAL MEDICINE JOURNAL, 2004, 34 (04) :187-191
[7]   Clinical features and natural history of nonalcoholic steatosis syndromes [J].
Falck-Ytter, Y ;
Younossi, ZM ;
Marchesini, G ;
McCullough, AJ .
SEMINARS IN LIVER DISEASE, 2001, 21 (01) :17-26
[8]  
Laurin J, 1996, HEPATOLOGY, V23, P1464
[9]   Metformin in non-alcoholic steatohepatitis [J].
Marchesini, G ;
Brizi, M ;
Bianchi, G ;
Tomassetti, S ;
Zoli, M ;
Melchionda, N .
LANCET, 2001, 358 (9285) :893-894
[10]  
MATHEWS DR, 1985, DIABETOLOGIA, V28, P412